ALPS Advisors’s Maravai LifeSciences MRVI Stock Holding History

ALPS Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-21,665	Closed	-$269K	–	1079
2023 Q2	$269K	Buy	21,665 +165	+0.8%	+$2.23K	﹤0.01%	927
2023 Q1	$301K	Buy	+21,500	New	+$309K	﹤0.01%	872
2022 Q3	–	Sell	-8,978	Closed	-$255K	–	1152
2022 Q2	$255K	Sell	8,978 -93	-1%	-$2.95K	﹤0.01%	934
2022 Q1	$320K	Buy	9,071 +1,132	+14%	+$37.9K	﹤0.01%	745
2021 Q4	$333K	Buy	7,939 +158	+2%	+$6.4K	﹤0.01%	808
2021 Q3	$382K	Buy	+7,781	New	+$380K	﹤0.01%	603

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

ALPS Advisors's MRVI Position: Q3 2023 in Review

ALPS Advisors sold out of Maravai LifeSciences (MRVI) in Q3 2023, closing a stake of 21,665 shares — an estimated $269K sold.

ALPS Advisors first reported a position in MRVI in Q3 2021 and held it in 6 quarters. The position peaked at $382K in Q3 2021. 204 funds tracked by Wall St. Rank hold MRVI as of Q3 2023.

ALPS Advisors reported no remaining Maravai LifeSciences position as of Q3 2023 after selling out during the quarter.
ALPS Advisors sold 21,665 Maravai LifeSciences shares in Q3 2023, an estimated $269K.
ALPS Advisors first reported a position in Maravai LifeSciences in Q3 2021 and held it in 6 quarters.
ALPS Advisors's Maravai LifeSciences position peaked at $382K in Q3 2021.
204 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2023.

Based on ALPS Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.